Bosco Cecilia, Crawley Danielle, Adolfsson Jan, Rudman Sarah, Van Hemelrijck Mieke
King's College London, School of Medicine, Division of Cancer Studies, Cancer Epidemiology Group, London, United Kingdom.
King's College London, School of Medicine, Division of Cancer Studies, Cancer Epidemiology Group, London, United Kingdom; Department of Oncology, Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom.
PLoS One. 2015 Mar 20;10(3):e0117344. doi: 10.1371/journal.pone.0117344. eCollection 2015.
No meta-analysis is yet available for the risk of metabolic syndrome (MetS) following androgen deprivation therapy (ADT) for men with prostate cancer. To summarize the evidence for the link between ADT and MetS or its components quantitatively with a meta-analysis including all studies published to date.
PubMed and Embase were searched using predefined inclusion criteria to perform meta-analyses on the association between metabolic syndrome, hyperglycemia, diabetes, hypertension, dyslipidemia or obesity and androgen deprivation therapy in patients with prostate cancer. Random effects methods were used to estimate pooled relative risks (RRs) and 95% confidence intervals (CI).
A total of nine studies was included. There was a positive association between ADT and risk of MetS (RR: 1.75 (95% CI: 1.27-2.41)). Diabetes was the only MetS component present in more than 3 studies, and also showed an increased risk following ADT (RR: 1.36 (95% CI: 1.17-1.58)).
This is the first quantitative summary addressing the potential risk of MetS following ADT in men with PCa. The positive RRs indicate that there is a need to further elucidate how type and duration of ADT affect these increased risks of MetS and diabetes as the number of men with PCa treated with ADT is increasing.
目前尚无关于前列腺癌男性患者接受雄激素剥夺治疗（ADT）后发生代谢综合征（MetS）风险的荟萃分析。通过荟萃分析对ADT与MetS或其组成部分之间的关联进行定量总结，纳入所有已发表的研究。
使用预定义的纳入标准检索PubMed和Embase，对前列腺癌患者中代谢综合征、高血糖、糖尿病、高血压、血脂异常或肥胖与雄激素剥夺治疗之间的关联进行荟萃分析。采用随机效应方法估计合并相对风险（RRs）和95%置信区间（CI）。
共纳入9项研究。ADT与MetS风险之间存在正相关（RR：1.75（95%CI：1.27 - 2.41））。糖尿病是超过3项研究中唯一出现的MetS组成部分，且在ADT后风险也增加（RR：1.36（95%CI：1.17 - 1.58））。
这是第一项针对前列腺癌男性患者ADT后MetS潜在风险的定量总结。RR为正值表明，随着接受ADT治疗的前列腺癌男性数量增加，有必要进一步阐明ADT的类型和持续时间如何影响这些MetS和糖尿病风险的增加。
